Mavenclad (Cladribine)

Mavenclad is a purine antimetabolite widely used to treat relapsing forms of MS (multiple sclerosis), including active secondary progressive disease and relapsing-remitting disease, in adults. Due to its safety point of view, Mavenclad (Cladribine) is generally used in individuals who have used another multiple sclerosis medicine that they could not tolerate or that has not worked effectively. 

Limitations of Use: Do not use Mavenclad 10 mg tablets in patients with clinically isolated syndrome (CIS).

Recommended Dosage: The recommended cumulative Mavenclad dosage is 3.5mg per kg body weight over two years, given as 1 therapy course of 1.75mg per kg yearly. Each therapy course typically consists of two therapy weeks, 1 at the start of the first month and 1 at the start of the second month of the respective therapy year. In case medically required (e.g. for recovery of lymphocytes), the therapy course in year 2 can be delayed for up to 6 months. Each therapy week consists of 4 or 5 days on which a patient receives 10 mg or 20 mg (one or two tablets) as a single daily dose, depending on body weight.

After the 2 therapy courses, no further cladribine 10 mg therapy is needed in 3 and 4 years. Restart of therapy with cladribine tablets after year 4 has not been evaluated. Tablets of Mavenclad are taken orally, with the help of water, and gulped whole without chewing. Tablets may be administered either with or without a meal. Separate use of this medication and any other oral medicine by a minimum of 3 hours during the 4-5 days of treatment cycles. In case a dose of Mavenclad 10 mg tablet is skipped or missed, patients should not take any additional or double doses. 

• Treatment with Mavenclad 10 mg may enhance the risk of malignancy. This medicine is not for use in those with current malignancy. In those with prior malignancy or with a higher probability of malignancy, assess the benefits as well as risks of the use of this medication on an individual patient basis. 
  
• Mavenclad may cause fetal harm if administered to pregnant women. In females of reproductive age, pregnancy needs to be excluded prior to initiating each treatment course of Cladribine and prevented by the use of appropriate contraception during treatment and for at least six months after the final dose of each treatment course.
  
• Cladribine 10 causes a dose-dependent demotion in lymphocyte count. Complete blood count (CBC) must be obtained with a differential including lymphocyte count before, during, and after therapy with Mavenclad tablets. 
  
• The medicine Cladribine can decrease the body’s immune defense and may trigger the likelihood of infections. Active tuberculosis (TB), HIV infection, and active hepatitis must be excluded prior to initiating each therapy course of Cladribine.
  
• Administer all immunizations as per immunization guidelines before starting Mavenclad therapy. Live-attenuated or live vaccines should be used at least 4 to 6 weeks before starting Mavenclad.

What documents are required to import MAVENCLAD® to India?

MAVENCLAD® (cladribine) tablets can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients Identity Proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

MAVENCLAD® (cladribine tablets) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of MAVENCLAD® in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of MAVENCLAD® (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for MAVENCLAD® (cladribine) price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug Mavenclad®?

Cladribine is a Generic Name for the trade name drug Mavenclad®.

What is the Manufacturer’s Name of Mavenclad®?

Mavenclad® is manufactured by EMD Serono, Inc.

Is Mavenclad® approved by the FDA?

Yes, Mavenclad® is approved by the FDA. Date of first/initial approval: March 29, 2019.

What is the dosage and form of Mavenclad® supplied?

Mavenclad® is supplied as Tablets: 10 mg for oral administration. 

What are the most common side effects of Mavenclad®? 

The most common side effects of Mavenclad® are headache, lymphopenia, and upper respiratory tract infection. 

How much does Mavenclad® cost in India?

Like other medicines, Mavenclad 10 mg cost in India can vary. In order to procure this medication legally, you can Call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Mavenclad®?

Store at a temperature of 20 to 25°C (68 to 77°F); excursions permitted to 15 to 30°C (59 to 86°F). Store the medicine in the original container to protect it from moisture. 

Is it safe to buy Mavenclad® online in India?

Yes, one can buy Mavenclad online in India at the lowest price from the Indian Pharma Network (IPN) if Mavenclad® is not (yet) registered or is unavailable in the respective country. We can help facilitate the Import of Mavenclad® tablets through legal channels.